Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06957327 · ClinicalTrials.gov registry record · Phase 1
A Study of ERAS-601 in People With Chordoma
A Phase 1 study of Chordoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 7
- Study locations
NCT06957327: Recruiting Phase 1 study of Chordoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06957327 is a Phase 1 study of Chordoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants, below the 84-participant average among 15 other Chordoma trials with a reported enrollment target (45% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06957327, a Phase 1 study of Chordoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Primary Outcome
proportion of patients with CR or PR at any time or SD ≥ 6 months per RECIST 1.1)
Conditions Studied
Interventions
- DRUG ERAS-601
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT06957327 shows while recruiting
NCT06957327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 84-participant average among 15 other Chordoma trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 1 intervention - of which ERAS-601 is the first listed.
NCT06957327 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT06957327 about?
NCT06957327 is a clinical study titled "A Study of ERAS-601 in People With Chordoma". The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
What is the current status of trial NCT06957327?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2025-04-25. Estimated completion is 2027-04.
What conditions does trial NCT06957327 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT06957327?
The interventions under investigation include: ERAS-601 (DRUG).
Who is sponsoring clinical trial NCT06957327?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06957327 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06957327's enrollment target sits among peer trials
46 7th of 15 higher than 9 of 15 other Chordoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chordoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
ACTIVE NOT RECRUITING · Phase 1
-
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
COMPLETED · Phase 1
-
Nilotinib With Radiation for High Risk Chordoma
COMPLETED · Phase 1
-
Children and Adults With Chordoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI